OWC Pharmaceutical Research Corp. (OTCMKTS:OWCP) Files An 8-K Other Events

OWC Pharmaceutical Research Corp. (OTCMKTS:OWCP) Files An 8-K Other Events
Item 8.01. Other Events.

Story continues below

OWC Pharmaceutical Research Corp. (the “Registrant”), is filing with this Form 8-K, a link to a video interview of Dr. Stanley Hirsch, Chairman of the Registrant’s Board of Directors, conducted by Mike Elliott of CEOlive at the 2018 Wall Street Conference held in Deerfield Beach, FL on February 21, 2018. The link to the video conference referenced in Exhibit 99.1 hereto, is: https://www.youtube.com/watch?v=VkW7_56ZSv0&feature=youtu.be

For information regarding the Registrant and to view its news and video releases including the interview of Dr. Hirsch, please visit the Registrant’s website at:


Item 9.01 Financial Statements and Exhibits.

(a) The following documents are filed as exhibits to this report on Form 8-K or incorporated by reference herein. Any document incorporated by reference is identified by a parenthetical reference to the SEC filing that included such document.

OWC Pharmaceutical Research Corp. Exhibit
EX-99.1 2 ex99-1.htm   Exhibit 99.1   https://www….
To view the full exhibit click here

About OWC Pharmaceutical Research Corp. (OTCMKTS:OWCP)

OWC Pharmaceutical Research Corp. is a medical cannabis research and development company. The Company is engaged in the research and development of cannabis-based medical products (the Product Prospects) for the treatment of multiple myeloma, psoriasis and fibromyalgia, as well as development of a cannabis soluble tablet delivery system that has applications for other indications. The Company also provides consulting services to governmental and private entities to assist them with developing and implementing various medical cannabis programs. As of September 30, 2016, the Company was engaged in two business activities: work with GUMI to commercialize and market the Company’s Electromagnetic Percussion Device (the Device), and research and development of Cannabis-based medical products for the treatment of a range of medical conditions and/or diseases, such as multiple myeloma, psoriasis, post-traumatic stress disorder (PTSD) migraines and a delivery system.

An ad to help with our costs